In this episode, Brenda Martone, MSN, ANP-BC, AOCNP describes recent evidence on PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) and discusses best practices for incorporating PARP inhibitors into clinical practice. Topics include:

• An overview of the PROpel study of olaparib and the TRITON study of rucaparib
• FDA-approved indications for olaparib and rucaparib
• Genetic and molecular testing for BRCA1/2 and other HRR mutations
• Managing adverse events associated with olaparib and rucaparib
• Monitoring for and managing anemia
• Gastrointestinal side effects
• Fatigue
• A look at the future of PARP inhibitors in mCRPC with combination approaches of AR-directed therapy and PARP inhibition

Presenter:
Brenda Martone, MSN, ANP-BC, AOCNP
Nurse Practitioner
Division of Genitourinary Oncology
Northwestern Medicine
Chicago, Illinois

Link to full program:
PCE.is/Onc22